193421-73-7

Upstream product

• 142035-33-4 ethyl N-(phenylmethylene)glycinate 
• 106-95-6 allyl bromide 
• 2835-06-5 phenylglycin 
• 6097-58-1 ethyl 2-phenyl-2-aminoacetate 

Downstream Products

• 144073-04-1 (RS)-2-amino-2-phenyl-4-penten-1-ol 
• 847027-69-4 (2S)-4-(2,5-difluorophenyl)-N-[(4R,6S)-6-fluoro-1-methylazepan-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide 
• 847027-70-7 (2S)-4-(2,5-difluorophenyl)-N-[(4S,6R)-6-fluoro-1-methylazepan-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide 
• 845256-48-6 (2S)-4-(2,5-difluorophenyl)-2-phenyl-2-[(1,1,2,2-tetramethylpropoxy)methyl]-2,5-dihydro-1H-pyrrole 
• 152375-59-2 (R)-α-allyl-α-phenylglycine ethyl ester 
• 149118-38-7 (R)-2-Phenyl-2-(2-propenyl)glycin 
• 84570-47-8 (S)-2-amino-2-phenylpent-4-enoic acid 

Relevant academic research and scientific papers

Highly enantioselective synthesis of β-amino alcohols

N,N-Dialkyl-β-amino alcohols derived from α-amino acids can be rearranged enantiospecifically by using TFAA/Et3N/NaOH to give 1,2-amino alcohols with enantiomeric excess up to 99%.

Mitotic kinesin inhibitors

The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention is also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

MITOTIC KINESIN INHIBITORS

The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

Mitotic kinesin inhibitors

The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention is also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.